Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) Estimate
Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.85) by 4.71 percent. This is a 24.3 percent increase over losses of $(1.07) per share
Cullinan lost less money per share than people expected, and it's losing less money than it did last year. When a company that's still losing money gets better at controlling costs, that's a sign it might be moving toward making a profit someday.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.